Ocular Therapeutix (OCUL) Net Margin (2014 - 2026)
Ocular Therapeutix's (OCUL) quarterly Net Margin came in at 835.11% in Q1 2026, down 24552.0% year-on-year from N/an in Q1 2025, and down 64.01% quarter-over-quarter from 509.18% in Q4 2025.
Ocular Therapeutix (OCUL) Net Margin (2014 - 2026) Analysis & Trends
Ocular Therapeutix's Net Margin history runs 13 years deep, the most recent figure standing at 835.11% for Q1 2026.
- On a quarterly basis, Net Margin fell 24552.0% year-over-year to 835.11% in Q1 2026; TTM through Mar 2026 was 562.49%, a 23320.0% decrease from a year earlier, with the FY2025 full-year figure at 1047.35%, down 45613.0% from the prior year.
- Net Margin declined to 835.11% in Q1 2026 per OCUL's latest filing, from 509.18% in the prior quarter.
- Across five years, Net Margin topped out at 115.89% in Q4 2022 and bottomed at 835.11% in Q1 2026.
- The 5-year median for Net Margin is 247.86% (2024), against an average of 310.07%.
- Across the five-year window, Net Margin jumped 15036 bps in 2022 and plunged 31437 bps in 2025, its largest moves.
- Year by year, Net Margin stood at 115.89% in 2022, then tumbled by 58 bps to 182.85% in 2023, then tumbled by 57 bps to 286.92% in 2024, then plunged by 77 bps to 509.18% in 2025, then plunged by 64 bps to 835.11% in 2026.
- Per Business Quant, the three latest OCUL Net Margin figures stand at 835.11% (Q1 2026), 509.18% (Q4 2025), and 467.35% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ocular Therapeutix | 1.93 Bn | 1.93 Bn | 9.46 Mn | -835.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -835.11% |
| Dec 31, 2025 | -509.18% |
| Sep 30, 2025 | -467.35% |
| Jun 30, 2025 | -499.31% |
| Mar 31, 2025 | -589.60% |
| Dec 31, 2024 | -286.92% |
| Sep 30, 2024 | -282.46% |
| Jun 30, 2024 | -247.86% |
| Mar 31, 2024 | -275.23% |
| Dec 31, 2023 | -182.85% |
| Sep 30, 2023 | -142.09% |
| Jun 30, 2023 | -143.64% |
| Mar 31, 2023 | -177.61% |
| Dec 31, 2022 | -115.89% |
| Sep 30, 2022 | -192.70% |
| Jun 30, 2022 | -175.60% |
| Mar 31, 2022 | -147.86% |
| Dec 31, 2021 | -160.25% |
| Sep 30, 2021 | -174.28% |
| Jun 30, 2021 | -186.70% |